Alemtuzumab for ANCA-Associated Refractory Vasculitis - A study of safety and efficacy (ALEVIATE).
- Registry ID
- EUCTR2009-017087-17
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Addenbrooke's Hospital
- Start date
- 2010-08-10
- Completion date
- 2018-05-29
- Last update
- 2026-08-16
Conditions
- ANCA-associated vasculitis (AAV)
Summary
There are 2 principal questions that this research will address: 1) Does alemtuzumab control ANCA associated vasculitis and provide a treatment free sustained remission, in patients that have disease resistant to current standard therapy? 2) Is this achieved with an acceptable level of serious adverse events (at or below levels seen with standard therapy)?
Locations
View on source registry